AbbVie Inc 8-K, filed Feb 5, 2025
AbbVie Inc. (ABBV)
About this 8-K
AbbVie Inc filed this 8-K on February 5, 2025, reporting on events of January 30, 2025.
Items reported
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
________________________________________________________________
(Address of principal executive offices)(Zip Code)
Registrant’s
telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name
of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events. |
Revolving Credit Agreement
On January 30, 2025 (the “Effective Date”), AbbVie Inc. (“AbbVie”) entered into a revolving credit agreement (the “Revolving Credit Agreement”) among AbbVie, as borrower, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Revolving Credit Agreement establishes an unsecured revolving credit facility of up to $3.0 billion which matures on January 30, 2030. This facility enables AbbVie to borrow funds on an unsecured basis at variable interest rates and contains various covenants. AbbVie had no borrowings outstanding under the Revolving Credit Agreement on the Effective Date. AbbVie’s existing $5.0 billion revolver maturing in March 2028 remains in effect, such that as of the Effective Date AbbVie has access to revolving credit facilities totaling $8.0 billion in the aggregate.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABBVIE INC. | ||
| By: | /s/ Scott T. Reents | |
| Date: February 5, 2025 | Name: | Scott T. Reents |
| Title: | Executive Vice President, Chief Financial Officer | |